BRPI0309665B8 - método para analisar uma preparação de alfagalactosidase a - Google Patents

método para analisar uma preparação de alfagalactosidase a

Info

Publication number
BRPI0309665B8
BRPI0309665B8 BRPI0309665A BR0309665A BRPI0309665B8 BR PI0309665 B8 BRPI0309665 B8 BR PI0309665B8 BR PI0309665 A BRPI0309665 A BR PI0309665A BR 0309665 A BR0309665 A BR 0309665A BR PI0309665 B8 BRPI0309665 B8 BR PI0309665B8
Authority
BR
Brazil
Prior art keywords
alpha
analyzing
galactosidase
galactosidase preparation
methods
Prior art date
Application number
BRPI0309665A
Other languages
English (en)
Other versions
BRPI0309665B1 (pt
BR0309665A (pt
Inventor
A Treco Douglas
Loveday Kenneth
Borowski Marianne
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Publication of BR0309665A publication Critical patent/BR0309665A/pt
Publication of BRPI0309665B1 publication Critical patent/BRPI0309665B1/pt
Publication of BRPI0309665B8 publication Critical patent/BRPI0309665B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

"tratamento de deficiência de alfagalactosidase a". a invenção provê métodos de tratamento de deficiência de <244>-galactosidase a. formas de dosagem, métodos de administração e métodos de análise de <244>-galactosidase a humana são também incluídos.
BRPI0309665A 2002-04-25 2003-04-25 método para analisar uma preparação de alfagalactosidase a BRPI0309665B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37558402P 2002-04-25 2002-04-25
US60/375,584 2002-04-25
PCT/US2003/013063 WO2003090695A2 (en) 2002-04-25 2003-04-25 TREATMENT OF α-GALACTOSIDASE A DEFICIENCY

Publications (3)

Publication Number Publication Date
BR0309665A BR0309665A (pt) 2005-08-16
BRPI0309665B1 BRPI0309665B1 (pt) 2019-07-16
BRPI0309665B8 true BRPI0309665B8 (pt) 2021-05-25

Family

ID=29270665

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0309665A BRPI0309665B8 (pt) 2002-04-25 2003-04-25 método para analisar uma preparação de alfagalactosidase a
BR122017016940A BR122017016940B8 (pt) 2002-04-25 2003-04-25 método para preparação de uma composição farmacêutica compreendendo alfa-galactosidase a

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122017016940A BR122017016940B8 (pt) 2002-04-25 2003-04-25 método para preparação de uma composição farmacêutica compreendendo alfa-galactosidase a

Country Status (13)

Country Link
US (6) US20040071686A1 (pt)
EP (2) EP1503788B1 (pt)
JP (5) JP5570677B2 (pt)
AT (1) ATE514430T1 (pt)
AU (2) AU2003228722B2 (pt)
BR (2) BRPI0309665B8 (pt)
CA (1) CA2483270C (pt)
DK (1) DK1503788T3 (pt)
ES (1) ES2367257T3 (pt)
HK (1) HK1073608A1 (pt)
IL (4) IL164757A0 (pt)
NZ (1) NZ536361A (pt)
WO (1) WO2003090695A2 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ536361A (en) 2002-04-25 2008-05-30 Shire Human Genetic Therapies Treatment of alpha-galactosidase a deficiency
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CA2621250A1 (en) 2004-09-07 2006-03-16 Zymequest, Inc. Apparatus for prolonging survival of platelets
ATE495667T1 (de) * 2004-10-15 2011-02-15 Velico Medical Inc Zusammensetzungen und verfahren für die verlängerung der überlebensdauer von blutplättchen
WO2007097934A2 (en) * 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
US20100144008A1 (en) * 2006-12-21 2010-06-10 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
AU2008290217B2 (en) 2007-08-20 2013-09-05 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
EP2185187A1 (en) * 2007-08-29 2010-05-19 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
US20120230974A1 (en) * 2009-11-17 2012-09-13 Protalix Ltd Alkaline alpha galactosidase for the treatment of fabry disease
DK3103469T3 (en) * 2010-06-25 2021-02-22 Shire Human Genetic Therapies Indgivelse af terapeutiske midler til centralnervesystemet
JP6045492B2 (ja) 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
DK2585104T3 (da) 2010-06-25 2019-10-14 Shire Human Genetic Therapies Fremgangsmåder og sammensætninger tilcns-levering af arylsulfatase a
IL291554B2 (en) * 2010-06-25 2024-02-01 Shire Human Genetic Therapies Administering therapeutic agents to the central nervous system
AU2012204526B2 (en) 2011-01-03 2016-05-19 California Institute Of Technology High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury
LT3272861T (lt) 2011-01-20 2020-03-25 Protalix Ltd. Alfa-galaktozidazės kompozicijos
HUE038020T2 (hu) * 2011-07-14 2018-09-28 Grifols Sa Fehérje-szializáció gyors és pontos analízise
EP2776120B1 (en) 2011-11-11 2020-09-09 Neuroenabling Technologies, Inc. Non invasive neuromodulation device for enabling recovery of motor, sensory, autonomic, sexual, vasomotor and cognitive function
EP2793922B1 (en) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
EP2874648A4 (en) * 2012-07-17 2015-12-30 Amicus Therapeutics Inc CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
AU2014342232B2 (en) * 2013-10-31 2017-12-21 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
BR112017013300A2 (pt) 2014-12-22 2018-02-27 Codexis Inc alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2017170896A1 (ja) * 2016-03-30 2017-10-05 国立大学法人徳島大学 マンノース－６－リン酸基含有糖蛋白質の製造方法、及び蛍光基結合型マンノース－６－リン酸基含有糖蛋白質の細胞内分布を検出する方法
EP3565583A4 (en) * 2017-01-05 2020-12-02 Protalix Ltd. TREATMENT DIET FOR THE TREATMENT OF FABRY'S DISEASE USING STABILIZED ALPHA-GALACTOSIDASE
TW201829770A (zh) 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A
EP3974021B1 (en) 2017-06-30 2023-06-14 ONWARD Medical N.V. A system for neuromodulation
JP7252211B2 (ja) * 2017-09-08 2023-04-04 ザ ヌムール ファウンデーション リソソーム蓄積症を治療するための薬剤、デバイス、および血液循環システム、ならびにリソソーム蓄積症を治療するための方法
EP3720338A1 (en) 2017-12-05 2020-10-14 Ecole Polytechnique Federale de Lausanne (EPFL) A system for planning and/or providing neuromodulation
DE18205821T1 (de) 2018-11-13 2020-12-24 Gtx Medical B.V. Steuerungssystem zur bewegungsrekonstruktion und/oder wiederherstellung für einen patienten
BR112021011750A2 (pt) 2018-12-20 2021-08-31 Codexis, Inc. Alfa-galactosidase a recombinante e/ou fragmento de alfa-galactosidase a recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa-galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições
EP3695878B1 (en) 2019-02-12 2023-04-19 ONWARD Medical N.V. A system for neuromodulation
EP3827871A1 (en) 2019-11-27 2021-06-02 ONWARD Medical B.V. Neuromodulation system
AU2021228689A1 (en) * 2020-02-28 2022-09-01 Codexis, Inc. Human alpha-galactosidase variants

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658567A (en) * 1899-10-14 1900-09-25 Elmer G Howard Threshing-machine attachment.
US4407957A (en) * 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
EP0159604B1 (en) 1984-04-09 1990-11-07 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
US4764376A (en) * 1984-06-18 1988-08-16 Eli Lilly And Company Method of inhibiting aromatase
GB8530631D0 (en) * 1985-12-12 1986-01-22 Ciba Geigy Ag Thrombin inhibitors
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5272066A (en) * 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
WO1990011353A1 (en) 1989-03-24 1990-10-04 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5179023A (en) * 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5382518A (en) * 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
ATE154362T1 (de) * 1989-09-05 1997-06-15 Biotech Australia Pty Ltd Verfahren zur herstellung von pai-2
JP2688854B2 (ja) 1989-10-27 1997-12-10 株式会社ホーネンコーポレーション 糖転移活性の強いα―ガラクトシダーゼの製造法
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5661132A (en) * 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
EP0550675A1 (en) 1990-09-28 1993-07-14 Cephalon, Inc. Transgenic animals with alzheimer's amyloid precursor gene
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
CA2099876C (en) 1991-01-21 2002-03-26 Michael L. Hayes Production of enzymatically active glucocerebrosidase from recombinant cells
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
ATE189124T1 (de) 1991-07-02 2000-02-15 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
WO1993008292A1 (en) 1991-10-16 1993-04-29 Agracetus, Inc. Particle-mediated transformation of animal somatic cells
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5858751A (en) * 1992-03-09 1999-01-12 The Regents Of The University Of California Compositions and methods for producing sialyltransferases
DE69312487T2 (de) 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5804413A (en) * 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
BR9307141A (pt) 1992-09-29 1999-03-30 Inhale Therapeutic Syst Processo para a liberação sistência pulsátil de um fragmento ativo de hormônio de paratiróide (PTH) para um hospedeiro mamífero e para um paciente e composição farmacêutica
US6329191B1 (en) 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
EP0726964A4 (en) * 1993-09-23 1999-01-13 New England Biolabs Inc INSULATION AND COMPOSITION OF NEW GLYCOSIDASES
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5843015A (en) 1993-12-28 1998-12-01 Becton Dickinson And Company Molecules for iontophoretic delivery
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
AU4424497A (en) 1996-09-13 1998-04-02 Transkaryotic Therapies, Inc. Therapy for alpha-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
AU766620B2 (en) 1998-05-07 2003-10-23 Shire Human Genetic Therapies, Inc. Modifying the expression of the fsh beta gene by homologous recombination
CZ299460B6 (cs) 1998-05-07 2008-08-06 Shire Human Genetic Therapies, Inc. DNA konstrukt, izolovaná molekula nukleové kyseliny, homologne rekombinantní bunka a její použití azpusob produkce G-CSF
IL125423A (en) * 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
NZ536361A (en) * 2002-04-25 2008-05-30 Shire Human Genetic Therapies Treatment of alpha-galactosidase a deficiency

Also Published As

Publication number Publication date
JP2018016630A (ja) 2018-02-01
IL280818B (en) 2021-12-01
EP1503788B1 (en) 2011-06-29
US20160184409A1 (en) 2016-06-30
CA2483270A1 (en) 2003-11-06
BRPI0309665B1 (pt) 2019-07-16
US9267166B2 (en) 2016-02-23
IL220043A0 (en) 2012-06-28
JP2005538941A (ja) 2005-12-22
WO2003090695A3 (en) 2004-05-06
IL257056B (en) 2021-03-25
IL280818A (en) 2021-04-29
US11116823B2 (en) 2021-09-14
JP2016180003A (ja) 2016-10-13
IL220043B (en) 2018-02-28
JP6225224B2 (ja) 2017-11-01
AU2003228722B2 (en) 2009-06-25
AU2009217430B2 (en) 2012-10-18
AU2009217430A1 (en) 2009-10-15
DK1503788T3 (da) 2011-10-17
BR122017016940B8 (pt) 2021-07-27
JP2012140431A (ja) 2012-07-26
US20060177433A1 (en) 2006-08-10
BR0309665A (pt) 2005-08-16
ES2367257T3 (es) 2011-10-31
HK1073608A1 (en) 2005-10-14
CA2483270C (en) 2015-03-31
EP1503788A4 (en) 2008-09-03
BR122017016940B1 (pt) 2020-11-10
JP5570677B2 (ja) 2014-08-13
JP5981151B2 (ja) 2016-08-31
NZ536361A (en) 2008-05-30
EP1503788A2 (en) 2005-02-09
US9523113B2 (en) 2016-12-20
US7833742B2 (en) 2010-11-16
JP6492139B2 (ja) 2019-03-27
AU2003228722A1 (en) 2003-11-10
US20190255156A1 (en) 2019-08-22
EP2361631A1 (en) 2011-08-31
US20040071686A1 (en) 2004-04-15
ATE514430T1 (de) 2011-07-15
US20110002908A1 (en) 2011-01-06
US20170216411A1 (en) 2017-08-03
US10245304B2 (en) 2019-04-02
IL164757A0 (en) 2005-12-18
WO2003090695A2 (en) 2003-11-06
IL257056A (en) 2018-06-28
JP2014196343A (ja) 2014-10-16

Similar Documents

Publication Publication Date Title
BRPI0309665B8 (pt) método para analisar uma preparação de alfagalactosidase a
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
WO2003087831A3 (en) Proteins involved in breast cancer
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
MY151032A (en) Treatment of tnf? related disorders
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DK1472541T3 (da) Afbildningsmidler og metoder til at afbilde NAALADase og PSMA
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2005107726A3 (en) Method for the treatment of back pain
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
TW200507840A (en) Method of treating multiple myeloma
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
DE50214008D1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
SE0202608D0 (sv) New sequences

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/04/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: SHIRE HUMAN GENETICS THERAPIES, INC. (US)

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 25/04/2023